Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 17/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3620974 | 0.90 | CHRM3 (0.62) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL3607902 | 0.89 | CHRM3 (0.60) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL13545705 | 0.87 | CHRM3 (0.53) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL15015184 | 0.83 | CHRM3 (0.64) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL3618917 | 0.82 | ALDH1A1 (0.40) | CHRM3CHRM2CHRM1CYP2D6ALDH1A1 | |
| SCHEMBL3620432 | 0.82 | CHRM3 (0.52) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL3622658 | 0.81 | CHRM3 (0.70) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL3612214 | 0.81 | CHRM3 (0.62) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL3618425 | 0.81 | CHRM3 (0.62) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL3617862 | 0.80 | CHRM3 (0.60) | CHRM3CHRM2CHRM1KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-21 | — | — | US | disclosed |
| EP-1828174-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006054162-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.